Summary: In 132 adults who had regained at least 10% of total body weight after Roux-en-Y gastric bypass, 56 weeks of liraglutide 3.0 mg produced a mean total body weight loss of 8.8% versus a 1.1% gain on placebo, and 76% versus 17% reached at least 5% loss. The trial was single-centre and disrupted by the pandemic, so the result is promising rather than definitive.
PICO Summary
| Element | Detail |
|---|---|
| Population | 132 adults (RCT, single university hospital, United States) who had achieved at least 25% total body weight loss after Roux-en-Y gastric bypass and then regained at least 10% from nadir, 18 to 120 months post-surgery. |
| Intervention | Liraglutide 3.0 mg by daily subcutaneous injection plus lifestyle counselling for 56 weeks (n = 89). |
| Comparison | Matching placebo injection plus lifestyle counselling for 56 weeks (n = 43). |
| Outcome | Mean change in total body weight at 56 weeks was -8.8% with liraglutide versus +1.1% with placebo. At least 5% loss was reached by 76% versus 17%; at least 10% loss by 51% versus 0%; and at least 15% loss by 26% of the liraglutide group. 21% of liraglutide subjects fell below their post-operative nadir weight versus 0% on placebo. A cross-check reported an estimated between-group difference of about -9.9% (95% CI 6.3 to 13.6); formal CI and p values are not given in the abstract. Non-serious adverse events occurred in 41.6% on liraglutide; serious adverse events were less frequent on liraglutide. Trial completion was reduced by the pandemic (65% liraglutide, 53.4% placebo). |
Liraglutide 3.0 mg for Weight Recurrence After RYGB
RCT · post-bypass weight regain · 56 weeks
Liraglutide 3.0 mg produced a mean 8.8% weight loss versus a 1.1% gain on placebo (about a 9.9% between-group difference) in weight regain after gastric bypass, but the single-centre, pandemic-disrupted design makes the estimate promising rather than definitive.
Expert Commentary
Weight recurrence after gastric bypass is common and frustrating, and this trial offers a reasonable, well-aligned answer. The verdict is positive: in a double-blind, placebo-controlled design, liraglutide 3.0 mg produced a clinically meaningful separation from placebo, with most treated patients losing at least 5% of body weight and roughly one in five dropping below their surgical nadir, all without an excess of serious adverse events. The direction and magnitude were independently confirmed against the published figures. The most important limitation is fragility of the evidence base. This was a single-centre study of 132 patients with unequal allocation, and the pandemic cut completion to around half in the placebo arm, which inflates the risk that attrition and a small sample distort the estimate. The reported between-group difference should therefore be read as encouraging rather than precise, and replication in larger multi-centre trials is needed. Can I use this with my patients? Cautiously yes, for the specific patient who has regained weight after Roux-en-Y bypass and can tolerate daily injections and the predictable gastrointestinal effects, framed as an adjunct to ongoing lifestyle support rather than a guarantee. Worth noting that 3.0 mg liraglutide is a manufacturer-marketed anti-obesity dose and the abstract does not state the funding source. Clinicians should set realistic expectations and monitor tolerability.
References
Lofton HF, Maranga G, Hold R, Fielding G, Youn H, Gujral A, et al. A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2025;21(2):135-145. doi:10.1016/j.soard.2024.08.037